2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006090967v1 18/8/2311    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suganuma, E. Articles by Kon, V. Search for Related Content PubMed PubMed Citation Articles by Suganuma, E. Articles by Kon, V. Related Collections Related Article

Angiotensin Inhibition Decreases Progression of Advanced Atherosclerosis and Stabilizes Established Atherosclerotic Plaques

Eisuke Suganuma^*, Vladimir R. Babaev, Masaru Motojima^*, Yiqin Zuo^*, Nobuhiko Ayabe^*, Agnes B. Fogo^*,,, Iekuni Ichikawa^*, MacRae F. Linton^,, Sergio Fazio^, and Valentina Kon^*

Departments of ^* Pediatrics, Medicine, Pathology, and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee

Correspondence: Dr. Valentina Kon, Vanderbilt University Medical Center, Nashville, TN 37232-2584. Phone: 615-322-7416; Fax: 615-322-7929; E-mail: valentina.kon{at}vanderbilt.edu

Received for publication September 6, 2006. Accepted for publication April 30, 2007.

Although increased extracellular matrix (ECM) is pathogenic in a variety of chronic tissue injuries, reduced and/or disrupted ECM may be detrimental in atherosclerosis and rather destabilize existing atherosclerotic lesions. This study therefore assessed the effects of angiotensin II (AngII) antagonism on ECM components of advanced atherosclerosis. Twenty-four-week-old apolipoprotein E–deficient mice were treated with the AngII antagonist losartan for 12 wk. Controls received water or hydralazine. AngII antagonism significantly reduced progression of established atherosclerosis, whereas hydralazine showed no benefit despite similar decrease in BP. Although there was no difference in the macrophage component, AngII antagonism increased the relative collagen portion of the lesions; lessened elastin fragmentation, increased the total elastin content of the aorta; and reduced the mRNA and activity/protein of the elastolytic proteases, cathepsin S, and metalloproteinase-9. Extracellular elastin degradation by cultured smooth muscle cells (SMC) was reduced by losartan, as was SMC invasion through an elastin gel barrier. Thus, AngII antagonism lessens progression of atherosclerosis, increases collagen, and preserves elastin components of ECM within the vascular lesions, which, at least in part, is modulated by effects on SMC. These effects not only decrease further expansion of advanced lesions but also stabilize the established atherosclerotic plaques and may underlie the decreased incidence of acute cardiovascular events that are observed in patients in whom AngII antagonism is begun after atherosclerosis is already established.

Related Article

This Month's Highlights
J. Am. Soc. Nephrol. 2007 18: A13. [Full Text] [PDF]

This article has been cited by other articles:

				X. W. Cheng, T. Murohara, M. Kuzuya, H. Izawa, T. Sasaki, K. Obata, K. Nagata, T. Nishizawa, M. Kobayashi, T. Yamada, et al. Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment Am. J. Pathol., August 1, 2008; 173(2): 358 - 369. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673